What Is Asceniv, and Why Does It Matter?
Asceniv (immune globulin intravenous) is a ready-to-use prescription medicine given intravenously. It contains concentrated human immunoglobulin G (IVIG) made from donated human plasma and is used to treat primary humoral immunodeficiency (PI). The FDA has expanded Asceniv’s use to treat this condition to include children 2 years old and older.
PI is a primary immune deficiency disease and comprises a group of inherited immune disorders caused by the defective development or function of B cells (a type of white blood cell), resulting in low levels or poor quality of special proteins called antibodies (immunoglobulins) that help the immune system fight against various infectious germs. Affected children are particularly susceptible to recurrent, often severe, bacterial or viral infections that most commonly involve the respiratory tract, with the risk beginning early in life once antibodies derived from the mother decline. Because antibody deficiency can be difficult to distinguish from frequent childhood infections, diagnosis is often delayed; however, early identification and treatment with intravenous immunoglobulin can restore protective antibody levels, reduce the risk for serious infections, and improve long‑term clinical outcomes.
Asceniv is a replacement medicine containing a wide range of naturally occurring, ready-made polyclonal antibodies known as immunoglobulin G (IgG). Asceniv is made from plasma collected at FDA‑approved facilities and undergoes strict testing and a patented screening process that combines regular plasma with plasma containing antibodies against respiratory syncytial virus (a common respiratory virus), providing broader immune protection. Although its exact mechanism of action is unknown, Asceniv is believed to help the immune system recognize and combat infection-causing bacteria, viruses, and their toxins.
This approval matters because the updated label now includes children 2 and older, allowing younger children to start their therapy earlier under the approved labeling.
Why Was It Approved?
The FDA’s approval is based on data that showed that Asceniv prevented acute serious bacterial infections and hospitalizations due to infections in patients, including children aged 2-11, with PI.
In one clinical study involving 16 children aged 2-11 with PI, Asceniv infusions were given every three or four weeks (based on the dose and schedule of their previous therapy) for about five months. During six months of observation, no serious bacterial infections such as blood poisoning (sepsis), infection of the brain and spinal cord lining (bacterial meningitis), bone or joint infections, bacterial pneumonia, or deep internal abscesses occurred. The study’s main goal to keep the rate of these infections below one per person each year was fulfilled. Additionally, no hospital stays due to infections were reported in that timeframe.
In another clinical study involving adults, teens, and children with PI who were already on regular IVIG therapy, Asceniv was infused every three to four weeks for 12 months. No serious bacterial infections were recorded during the observation period, confirming similar results and supporting the inclusion of a broader age range on the label.
Common side effects seen in studies included headache, sinus symptoms, diarrhea, nausea, viral gastroenteritis, colds, upper respiratory tract infections, and bronchitis.
What Do I Need to Know?
Asceniv is a liquid solution and given only through a vein as an infusion. Your child receives doses on a repeated schedule, often every three to four weeks. During infusions, your health care provider checks your child’s vital signs and may slow or stop the infusion if your child develops adverse reactions.
Immune globulin treatments (IVIG), including Asceniv, can cause blood clots (thrombosis), irritation of the brain’s lining (aseptic meningitis syndrome), anemia due to the breakdown of red blood cells (hemolytic anemia), and lung problems due to fluid buildup linked to transfusion. Therefore, your health care provider will closely monitor your child during treatment. If your child has a higher risk of thrombosis or thicker blood (hyperviscosity), your health care provider may use the lowest practical dose and infusion rate. Make sure that your child is well hydrated, and watch closely for any symptoms related to clots or thrombosis.
Immune globulin treatments (IVIG) such as Asceniv may also cause kidney problems, including sudden kidney failure. Be sure to inform your health care provider if your child has kidney problems. In case your child has a higher risk of developing kidney issues, your health care provider will perform certain blood tests to check your child’s kidney function before and during therapy.
Do not use Asceniv if your child has had a severe allergic (hypersensitivity or anaphylactic) reaction to human immune globulin. Do not use Asceniv if your child has immunoglobulin A (IgA) deficiency with antibodies against IgA and a history of hypersensitivity.
Asceniv can reduce how well certain live virus vaccines (such as measles, mumps, rubella, and varicella) work for a period of time. Tell your health care provider who gives vaccines if your child recently received Asceniv so that they can plan the vaccination schedule accordingly. Treatments involving passive transfer of antibodies can also interfere with the results of certain blood tests.
Contact your health care provider right away if your child shows any signs that could indicate a clot, such as sudden chest pain, shortness of breath, swollen legs, or a rapid heartbeat. Also call your health care provider if you notice signs of kidney problems in your child, such as decreased urine volume or sudden weight gain; if your child has a severe headache with a stiff neck, fever, eye pain, sensitivity to light, nausea, or vomiting; or yellowing of your child’s skin or eyes or passing dark urine, which can be signs of red blood cell breakdown. Any signs of lung problems such as unexplained shortness of breath; sudden chest pain or discomfort; rapid pulse; or blue lips, fingers, or toes indicate an emergency.